A presentation at ACR Convergence 2021 discussed the 2020 ACR Guideline for the Management of Gout, the latest information on the risk of cardiovascular death associated with febuxostat and the use of pegloticase for patients with gout.
Gout Research at a Glance: ‘My picks for the top research in gout presented at ACR Convergence 2021’
Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2021.
Colchicine: An Ancient Drug with Modern Uses
Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…
Case Report: Does a Young Woman with Gitelman Syndrome Have Gout?
Gout is the most common type of inflammatory arthritis in adults, and it typically occurs in men over the age of 50. When gout presents in younger patients or in women, this should warrant consideration of secondary causes. We describe an unusual genetic cause of tophaceous gout in a young, premenopausal woman. Case Report In…
Pegloticase Safe & Effective for Patients with Gout on Dialysis
Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.
Dr. Ethan Craig Picks His Favorite Gout Abstracts from ACR Convergence 2020
In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:
Optimize Gout Management with the Latest Evidence-Based Guidance
ACR Convergence 2020—In May 2020, the ACR published its updated guideline for the management of gout.1 It followed on the heels of a 2017 gout guideline published by the American College of Physicians.2 Although the guidelines provide similar recommendations on the treatment of acute gout, they differ importantly in the use of uric acid-lowering therapy…
FAST Results for Febuxostat Safety in Patients with Gout
ACR CONVERGENCE 2020—The results of a post-authorization study comparing the cardiovascular safety of febuxostat vs. allopurinol were presented in a late-breaking abstract session at the ACR’s fully virtual annual meeting on Monday, Nov. 9. Cardiologist Thomas MacDonald, MD, FRCP, MBChB, clinical professor (teaching and research) of molecular and clinical medicine, University of Dundee School of…
Lessons from Master Clinicians: An Interview with Dr. Alan Baer
Rheumatologists who are outstanding clinicians and provide consistent, exceptional care to patients are in the spotlight in our Lessons from a Master Clinician series. Here, we present insights from a clinician who has achieved distinction in the field of rheumatology, serving as a role model for colleagues and trainees. Alan Baer, MD, is currently a…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 21
- Next Page »